12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tafamidis: Extension study data

Data from 86 patients with a V30M mutation in the TTR gene in the 12-month, open-label Fx-006 extension of the double-blind, international Phase II/III Fx-005 trial showed that patients treated with tafamidis for 30 months had significantly less neurologic deterioration as measured by mean change from baseline in NIS-LL score vs. patients who received placebo...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >